Michel B.
- Country
- France
- Department
- CEA
Research Overview
- Longitudinal PET-MR Study on Myelin Repair and Neuroinflammation in Multiple Sclerosis
- Evaluation of Intravenous Ketamine Versus Placebo as Adjunct to Venlafaxine in Severe Unipolar Major Depressive Episodes: A Double-Blind Randomized Controlled Trial
- Quantification of Neuroinflammation in Multiple Sclerosis Using [18F]-DPA-714 PET Imaging: A Multicenter Study Comparing Lesion Activity in Patients and Healthy Controls
Data & Insights
Has run more than one trial at 2 of 12 partner sites.
Specializations
Neuroimaging and Brain PET Research
Michel BOTTLAENDER is involved in clinical research centred on advanced positron emission tomography and magnetic resonance imaging for neurological and psychiatric conditions, with a strong emphasis on molecular imaging of brain pathology.
- Alzheimer's disease and tau pathology
- Multiple sclerosis and remyelination
- Huntington's disease biomarkers
- Schizophrenia and neuroinflammation
His work also includes imaging-based evaluation of disease distribution, white matter involvement, and neurobiological markers linked to progression and therapeutic response.
Epilepsy and Neurosurgical Imaging
His clinical trial activity includes research on presurgical localisation in drug-resistant epilepsy, with a particular focus on identifying the epileptic focus through targeted molecular imaging.
- Seizure zone localisation
- SEEG-guided surgical candidates
- Preoperative brain mapping
This area reflects an interest in imaging tools that support decision-making in complex epilepsy care.
Psychiatry and Neurobiological Therapeutics
His research portfolio extends to psychiatric disorders, including major depressive disorder, early psychosis, and schizophrenia, with attention to functional outcomes and biologically informed treatment strategies.
- Severe depression
- Ultra high risk of psychosis
- Functional recovery in early psychosis
- Synaptic density and cortical neuroinflammation
He is also engaged in studies linking imaging biomarkers with clinical presentation in mood and psychotic disorders.
Oncology and Gastrointestinal Cancer
Michel BOTTLAENDER contributes to clinical research in solid tumours, especially colorectal cancer, rectal cancer, small bowel adenocarcinoma, and metastatic oeso-gastric adenocarcinoma, with interest in treatment selection and disease control.
- Locally advanced colorectal cancer
- Microsatellite unstable rectal cancer
- KRAS G12C-mutated colorectal adenocarcinoma
- Advanced gastro-oesophageal malignancies
His work also includes imaging and biomarker-oriented assessment in primary central nervous system lymphoma and other oncologic settings.
Critical Care and Infectious Disease
His trial activity includes acute care and hospital-based infectious disease research, with involvement in conditions managed in intensive care and surgical or paediatric settings.
- Septic shock
- Ventilator-associated pneumonia
- Complicated acute appendicitis
- Acute pyelonephritis in children
- Severe hyponatremia
These studies reflect a focus on clinically relevant interventions in acute medical and surgical care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.